We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Virus Caused Deaths of Transplant Recipients

By Biotechdaily staff writers
Posted on 10 May 2007
A new virus was responsible for the deaths of three transplant recipients who received organs from a single donor in Victoria, Australia. More...
Knowledge of genetic sequence of the virus will enable improvements in screening to enhance transplantation safety.

Scientists in the Greene Infectious Disease Laboratory of the Columbia University Mailman School of Public Health (New York, NY, USA) and colleagues in the Victorian Infectious Diseases Reference Laboratory in Melbourne (Australia) and 454 Life Sciences (Branford, CT, USA) have discovered a new virus that was responsible for the deaths of transplant recipients.

The previously unknown virus, which is related to lymphocytic choreomeningitis virus (LCMV), was found using rapid sequencing technology established by 454 Life Sciences and bioinformatics algorithms developed in the Greene Laboratory with support from the US National Institute of Allergy and Infectious Diseases. Known strains of LCMV have been implicated in a small number of cases of disease transmission by organ transplantation, however, the newly discovered virus is sufficiently different that it could not be detected using existing screening methods.

Over 30,000 organ transplants are performed in the United States each year. Knowledge of the genetic sequence of this virus will enable improvements in screening that will enhance the safety of transplantation.

Ian Lipkin, M.D., director of the Greene Laboratory and lead investigator of the Northeast Biodefense Center, emphasized the importance of academic, public health, and industrial partnership in this work. This was a team effort. Drs. Mike Catton and Julian Druce at the Victorian Infectious Disease Reference Laboratory reached out to us after a comprehensive state-of-the-art investigation failed to turn up leads, stated Dr. Lipkin. We succeeded in identifying the virus responsible for the deaths by building on their work and utilizing new tools for pathogen surveillance and discovery developed in the Greene Laboratory and 454 Life Sciences.


Related Links:
454 Life Sciences
Greene Infectious Disease Laboratory
Victorian Infectious Diseases Reference Laboratory

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.